6H-1,3,4-噻二嗪衍生物 L-36 化合物的抗血小板和抗血栓特性

IF 0.9 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Bulletin of Experimental Biology and Medicine Pub Date : 2024-07-02 DOI:10.47056/0365-9615-2024-177-1-74-79

V. Sirotenko, A. A. Spasov, A. Kucheryavenko, K. A. Gaidukova, A. V. Smirnov, Y. Velikorodnaya

{"title":"6H-1,3,4-噻二嗪衍生物 L-36 化合物的抗血小板和抗血栓特性","authors":"V. Sirotenko, A. A. Spasov, A. Kucheryavenko, K. A. Gaidukova, A. V. Smirnov, Y. Velikorodnaya","doi":"10.47056/0365-9615-2024-177-1-74-79","DOIUrl":null,"url":null,"abstract":"Compound L-36, a new derivative of 6H-1,3,4-thiadiazine, was studied in in vitro and in vivo experiments. This compound exhibits high antiplatelet and antithrombogenic activity. In in vitro experiments, compound L-36 by its antiplatelet activity (by IC50) was superior to acetylsalicylic acid by 9.4 times. In in vivo experiments, compound L-36 by its ED50 value was close to the comparison drug. On the model of pulmonary artery thrombosis, compound L-36 ensured better survival of experimental animals than acetylsalicylic acid. Morphological studies showed that compound L-36 effectively attenuated the thrombosis processes in the pulmonary tissue induced by intravenous injection of a thrombogenic mixture (epinephrine and collagen).","PeriodicalId":9331,"journal":{"name":"Bulletin of Experimental Biology and Medicine","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative.\",\"authors\":\"V. Sirotenko, A. A. Spasov, A. Kucheryavenko, K. A. Gaidukova, A. V. Smirnov, Y. Velikorodnaya\",\"doi\":\"10.47056/0365-9615-2024-177-1-74-79\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Compound L-36, a new derivative of 6H-1,3,4-thiadiazine, was studied in in vitro and in vivo experiments. This compound exhibits high antiplatelet and antithrombogenic activity. In in vitro experiments, compound L-36 by its antiplatelet activity (by IC50) was superior to acetylsalicylic acid by 9.4 times. In in vivo experiments, compound L-36 by its ED50 value was close to the comparison drug. On the model of pulmonary artery thrombosis, compound L-36 ensured better survival of experimental animals than acetylsalicylic acid. Morphological studies showed that compound L-36 effectively attenuated the thrombosis processes in the pulmonary tissue induced by intravenous injection of a thrombogenic mixture (epinephrine and collagen).\",\"PeriodicalId\":9331,\"journal\":{\"name\":\"Bulletin of Experimental Biology and Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-07-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Experimental Biology and Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.47056/0365-9615-2024-177-1-74-79\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Experimental Biology and Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.47056/0365-9615-2024-177-1-74-79","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

在体外和体内实验中研究了 6H-1,3,4-噻二嗪的新衍生物 L-36 化合物。该化合物具有很高的抗血小板和抗血栓形成活性。在体外实验中，化合物 L-36 的抗血小板活性（IC50）是乙酰水杨酸的 9.4 倍。在体内实验中，化合物 L-36 的 ED50 值与对比药物接近。在肺动脉血栓模型中，化合物 L-36 比乙酰水杨酸更能确保实验动物存活。形态学研究表明，静脉注射血栓形成混合物（肾上腺素和胶原蛋白）后，化合物 L-36 能有效减轻肺组织的血栓形成过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Antiplatelet and Antithrombotic Properties of Compound L-36, a 6H-1,3,4-Thiadiazine Derivative.

Compound L-36, a new derivative of 6H-1,3,4-thiadiazine, was studied in in vitro and in vivo experiments. This compound exhibits high antiplatelet and antithrombogenic activity. In in vitro experiments, compound L-36 by its antiplatelet activity (by IC50) was superior to acetylsalicylic acid by 9.4 times. In in vivo experiments, compound L-36 by its ED50 value was close to the comparison drug. On the model of pulmonary artery thrombosis, compound L-36 ensured better survival of experimental animals than acetylsalicylic acid. Morphological studies showed that compound L-36 effectively attenuated the thrombosis processes in the pulmonary tissue induced by intravenous injection of a thrombogenic mixture (epinephrine and collagen).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bulletin of Experimental Biology and Medicine 医学-医学：研究与实验

CiteScore

1.50

自引率

14.30%

发文量

265

审稿时长

2 months

期刊介绍： Bulletin of Experimental Biology and Medicine presents original peer reviewed research papers and brief reports on priority new research results in physiology, biochemistry, biophysics, pharmacology, immunology, microbiology, genetics, oncology, etc. Novel trends in science are covered in new sections of the journal - Biogerontology and Human Ecology - that first appeared in 2005. World scientific interest in stem cells prompted inclusion into Bulletin of Experimental Biology and Medicine a quarterly scientific journal Cell Technologies in Biology and Medicine (a new Russian Academy of Medical Sciences publication since 2005). It publishes only original papers from the leading research institutions on molecular biology of stem and progenitor cells, stem cell as the basis of gene therapy, molecular language of cell-to-cell communication, cytokines, chemokines, growth and other factors, pilot projects on clinical use of stem and progenitor cells. The Russian Volume Year is published in English from April.